Currently, there are 1.74B common shares owned by the public and among those 1.72B shares have been available to trade.
Insiders at the company have transacted a total of 94 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 39 of these insider trades were purchases, accounting for 388,626 shares. Insider sales of the common stock occurred on 55 occasions, with total insider shares sold totaling 343,931 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 112.46, down -0.41%. The company’s stock has a 5-day price change of -1.59% and 16.35% over the past three months. ABT shares are trading 1.44% year to date (YTD), with the 12-month market performance down to -0.53% lower. It has a 12-month low price of $89.67 and touched a high of $115.83 over the same period. ABT has an average intraday trading volume of 5.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.38%, 2.25%, and 6.46% respectively.
Institutional ownership of Abbott Laboratories (NYSE: ABT) shares accounts for 75.64% of the company’s 1.74B shares outstanding.
It has a market capitalization of $193.83B and a beta (3y monthly) value of 0.74. The stock’s trailing 12-month PE ratio is 34.19, while the earnings-per-share (ttm) stands at $3.27. The company has a PEG of 4.38 and a Quick Ratio of 1.23 with the debt-to-equity ratio at 0.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.67% over the week and 1.50% over the month.
Analysts forecast that Abbott Laboratories (ABT) will achieve an EPS of $0.96 for the current quarter, $1.11 for the next quarter and $5.11 for 2025. The lowest estimate earnings-per-share for the quarter is $0.94 while analysts give the company a high EPS estimate of $1.02. Comparatively, EPS for the current quarter was $0.94 a year ago. Earnings per share for the fiscal year are expected to increase by 4.12%, and 11.35% over the next financial year. EPS should shrink at an annualized rate of 7.80% over the next five years, compared to 19.74% over the past 5-year period.
